Abstract
High post-menopausal levels of the pituitary gonadotropin follicle-stimulating hormone (FSH) are strongly associated with the onset of Alzheimer’s disease (AD). We have shown recently that FSH directly activates the hippocampal FSH receptors (FSHRs) to drive AD-like pathology and memory loss in mice. To unequivocally establish a role for FSH in memory loss, we depleted the Fshr on a 3xTg background and utilized Morris Water Maze to study deficits in spatial memory. 3xTg;Fshr+/+ mice displayed impaired spatial memory at 5 months of age. The loss of memory acquisition and retrieval were both rescued in 3xTg;Fshr−/− mice and, to a lesser extent, in 3xTg;Fshr+/− mice—documenting clear gene–dose-dependent prevention of spatial memory loss. Furthermore, at 5 and 8 months, sham-operated 3xTg;Fshr−/− mice showed better memory performance during the learning and/or retrieval phases, further suggesting that Fshr deletion prevents age-related progression of memory deficits. This prevention was not seen when mice were ovariectomized, except in the 8-month-old 3xTg;Fshr−/− mice. There was also a gene–dose-dependent reduction mainly in the amyloid β40 isoform in whole brain extracts. Finally, serum FSH levels <8 ng/mL in 16-month-old APP/PS1 mice were associated with better retrieval of spatial memory. Collectively, the data provide compelling genetic evidence for a protective effect of inhibiting FSH signaling on the progression of spatial memory deficits in mice and lay a firm foundation for the use of an FSH-blocking agent for the early prevention of memory loss in post-menopausal women.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout






Similar content being viewed by others
Data availability
Data are available from the corresponding authors on reasonable request.
References
Andersen K, Launer LJ, Dewey ME, Letenneur L, Ott A, Copeland JR, EURODEM Incidence Research Group, et al. Gender differences in the incidence of AD and vascular dementia: The EURODEM Studies. Neurology. 1999;53:1992–7.
Fisher DW, Bennett DA, Dong H. Sexual dimorphism in predisposition to Alzheimer’s disease. Neurobiol Aging. 2018;70:308–24.
Laws KR, Irvine K, Gale TM. Sex differences in cognitive impairment in Alzheimer’s disease. World J Psychiatry. 2016;6:54–65.
Koran MEI, Wagener M, Hohman TJ, Alzheimer’s Neuroimaging I. Sex differences in the association between AD biomarkers and cognitive decline. Brain Imaging Behav. 2017;11:205–13.
Ratnakumar A, Zimmerman SE, Jordan BA, Mar JC. Estrogen activates Alzheimer’s disease genes. Alzheimers Dement. 2019;5:906–17.
Vina J, Lloret A. Why women have more Alzheimer’s disease than men: gender and mitochondrial toxicity of amyloid-beta peptide. J Alzheimers Dis. 2010;20:S527–533.
Matyi JM, Rattinger GB, Schwartz S, Buhusi M, Tschanz JT. Lifetime estrogen exposure and cognition in late life: the Cache County Study. Menopause. 2019;26:1366–74.
Zandi PP, Carlson MC, Plassman BL, Welsh-Bohmer KA, Mayer LS, Steffens DC, et al. Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. JAMA. 2002;288:2123–9.
O’Brien J, Jackson JW, Grodstein F, Blacker D, Weuve J. Postmenopausal hormone therapy is not associated with risk of all-cause dementia and Alzheimer’s disease. Epidemiol Rev. 2014;36:83–103.
Short RA, Bowen RL, O’Brien PC, Graff-Radford NR. Elevated gonadotropin levels in patients with Alzheimer disease. Mayo Clin Proc. 2001;76:906–9.
Bowen JD, Malter AD, Sheppard L, Kukull WA, McCormick WC, Teri L, et al. Predictors of mortality in patients diagnosed with probable Alzheimer’s disease. Neurology. 1996;47:433–9.
Casadesus G, Atwood CS, Zhu X, Hartzler AW, Webber KM, Perry G, et al. Evidence for the role of gonadotropin hormones in the development of Alzheimer disease. Cell Mol Life Sci. 2005;62:293–8.
Meethal SV, Smith MA, Bowen RL, Atwood CS. The gonadotropin connection in Alzheimer’s disease. Endocrine. 2005;26:317–26.
Jack CR Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12:207–16.
Greendale GA, Huang MH, Wight RG, Seeman T, Luetters C, Avis NE, et al. Effects of the menopause transition and hormone use on cognitive performance in midlife women. Neurology. 2009;72:1850–7.
Randolph JF Jr, Sowers M, Gold EB, Mohr BA, Luborsky J, Santoro N, et al. Reproductive hormones in the early menopausal transition: relationship to ethnicity, body size, and menopausal status. J Clin Endocrinol Metab. 2003;88:1516–22.
Randolph JF Jr, Zheng H, Sowers MR, Crandall C, Crawford S, Gold EB, et al. Change in follicle-stimulating hormone and estradiol across the menopausal transition: effect of age at the final menstrual period. J Clin Endocrinol Metab. 2011;96:746–54.
Greendale GA, Sowers M, Han W, Huang MH, Finkelstein JS, Crandall CJ, et al. Bone mineral density loss in relation to the final menstrual period in a multiethnic cohort: results from the Study of Women’s Health Across the Nation (SWAN). J Bone Miner Res. 2012;27:111–8.
Greendale GA, Sternfeld B, Huang M, Han W, Karvonen-Gutierrez C, Ruppert K, et al. Changes in body composition and weight during the menopause transition. JCI Insight. 2019;4:e124865.
Sowers MR, Finkelstein JS, Ettinger B, Bondarenko I, Neer RM, Cauley JA, et al. The association of endogenous hormone concentrations and bone mineral density measures in pre- and perimenopausal women of four ethnic groups: SWAN. Osteoporos Int. 2003;14:44–52.
Sowers MR, Greendale GA, Bondarenko I, Finkelstein JS, Cauley JA, Neer RM, et al. Endogenous hormones and bone turnover markers in pre- and perimenopausal women: SWAN. Osteoporos Int. 2003;14:191–7.
Sowers MR, Jannausch M, McConnell D, Little R, Greendale GA, Finkelstein JS, et al. Hormone predictors of bone mineral density changes during the menopausal transition. J Clin Endocrinol Metab. 2006;91:1261–7.
Geng W, Yan X, Du H, Cui J, Li L, Chen F. Immunization with FSHbeta fusion protein antigen prevents bone loss in a rat ovariectomy-induced osteoporosis model. Biochem Biophys Res Commun. 2013;434:280–6.
Han X, Guan Z, Xu M, Zhang Y, Yao H, Meng F, et al. A novel follicle-stimulating hormone vaccine for controlling fat accumulation. Theriogenology. 2020;148:103–11.
Ji Y, Liu P, Yuen T, Haider S, He J, Romero R, et al. Epitope-specific monoclonal antibodies to FSHbeta increase bone mass. Proc Natl Acad Sci USA. 2018;115:2192–7.
Liu P, Ji Y, Yuen T, Rendina-Ruedy E, DeMambro VE, Dhawan S, et al. Blocking FSH induces thermogenic adipose tissue and reduces body fat. Nature. 2017;546:107–12.
Sun L, Peng Y, Sharrow AC, Iqbal J, Zhang Z, Papachristou DJ, et al. FSH directly regulates bone mass. Cell. 2006;125:247–60.
Araujo AB, Wittert GA. Endocrinology of the aging male. Best Pract Res Clin Endocrinol Metab. 2011;25:303–19.
Xiong J, Kang SS, Wang Z, Liu X, Kuo TC, Korkmaz F, et al. FSH blockade improves cognition in mice with Alzheimer’s disease. Nature. 2022;603:470–6.
Gera S, Sant D, Haider S, Korkmaz F, Kuo TC, Mathew M, et al. First-in-class humanized FSH blocking antibody targets bone and fat. Proc Natl Acad Sci USA. 2020;117:28971–9.
Zhu LL, Blair H, Cao J, Yuen T, Latif R, Guo L, et al. Blocking antibody to the beta-subunit of FSH prevents bone loss by inhibiting bone resorption and stimulating bone synthesis. Proc Natl Acad Sci USA. 2012;109:14574–9.
Zhu LL, Tourkova I, Yuen T, Robinson LJ, Bian Z, Zaidi M, et al. Blocking FSH action attenuates osteoclastogenesis. Biochem Biophys Res Commun. 2012;422:54–8.
Xiong J, Kang SS, Wang M, Wang Z, Xia Y, Liao J, et al. FSH and ApoE4 contribute to Alzheimer’s disease-like pathogenesis via C/EBPbeta/delta-secretase in female mice. Nat Commun. 2023;14:6577.
Ryu V, Gumerova A, Korkmaz F, Kang SS, Katsel P, Miyashita S, et al. Brain atlas for glycoprotein hormone receptors at single-transcript level. Elife. 2022;11:e79612.
Webster SJ, Bachstetter AD, Van Eldik LJ. Comprehensive behavioral characterization of an APP/PS-1 double knock-in mouse model of Alzheimer’s disease. Alzheimers Res Ther. 2013;5:28.
Minkeviciene R, Ihalainen J, Malm T, Matilainen O, Keksa-Goldsteine V, Goldsteins G, et al. Age-related decrease in stimulated glutamate release and vesicular glutamate transporters in APP/PS1 transgenic and wild-type mice. J Neurochem. 2008;105:584–94.
Kannangara H, Cullen L, Miyashita S, Korkmaz F, Macdonald A, Gumerova A, et al. Emerging roles of brain tanycytes in regulating blood-hypothalamus barrier plasticity and energy homeostasis. Ann N Y Acad Sci. 2023;1525:61–9.
Palm R, Chang J, Blair J, Garcia-Mesa Y, Lee HG, Castellani RJ, et al. Down-regulation of serum gonadotropins but not estrogen replacement improves cognition in aged-ovariectomized 3xTg AD female mice. J Neurochem. 2014;130:115–25.
Casadesus G, Milliken EL, Webber KM, Bowen RL, Lei Z, Rao CV, et al. Increases in luteinizing hormone are associated with declines in cognitive performance. Mol Cell Endocrinol. 2007;269:107–11.
Berry A, Tomidokoro Y, Ghiso J, Thornton J. Human chorionic gonadotropin (a luteinizing hormone homologue) decreases spatial memory and increases brain amyloid-beta levels in female rats. Horm Behav. 2008;54:143–52.
Sims S, Barak O, Ryu V, Miyashita S, Kannangara H, Korkmaz F, et al. Absent LH signaling rescues the anxiety phenotype in aging female mice. Mol Psychiatry. 2023;28:3324–31.
Naz MSG, Rahnemaei FA, Tehrani FR, Sayehmiri F, Ghasemi V, Banaei M, et al. Possible cognition changes in women with polycystic ovary syndrome: a narrative review. Obstet Gynecol Sci. 2023;66:347–63.
Karamitrou EK, Anagnostis P, Vaitsi K, Athanasiadis L, Goulis DG. Early menopause and premature ovarian insufficiency are associated with increased risk of dementia: a systematic review and meta-analysis of observational studies. Maturitas. 2023;176:107792.
Slopien R. Neurological health and premature ovarian insufficiency - pathogenesis and clinical management. Prz Menopauzalny. 2018;17:120–3.
Pearre DC, Bota DA. Chemotherapy-related cognitive dysfunction and effects on quality of life in gynecologic cancer patients. Expert Rev Qual Life Cancer Care. 2018;3:19–26.
Gera S, Kuo TC, Gumerova AA, Korkmaz F, Sant D, DeMambro V, et al. FSH-blocking therapeutic for osteoporosis. Elife. 2022;11:e78022.
Rojekar S, Pallapati AR, Gimenez-Roig J, Korkmaz F, Sultana F, Sant D, et al. Development and biophysical characterization of a humanized FSH-blocking monoclonal antibody therapeutic formulated at an ultra-high concentration. Elife. 2023;12:e88898.
Nerattini M, Rubino F, Jett S, Andy C, Boneu C, Zarate C, et al. Elevated gonadotropin levels are associated with increased biomarker risk of Alzheimer’s disease in midlife women. Front. Dement. 2023;2:1303256.
Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, et al. Triple-transgenic model of Alzheimer’s disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron. 2003;39:409–21.
Vorhees CV, Williams MT. Morris water maze: procedures for assessing spatial and related forms of learning and memory. Nat Protoc. 2006;1:848–58.
Acknowledgements
Work at Icahn School of Medicine at Mount Sinai carried at the Center for Translational Medicine and Pharmacology was supported by R01 AG071870, R01 AG074092 and U01 AG073148 to TY and MZ; U19 AG060917 to CJR and MZ; and R01 DK113627 to MZ.
Author information
Authors and Affiliations
Contributions
Conceptualization: T Yuen, M Zaidi. Supervision: T Yuen, T Frolinger, M Zaidi. Scientific input: K Goosens, CJ Rosen, K Ye, V Ryu. Neurobehavioral studies: T Frolinger, F Korkmaz, S Sims, A Liu, R Chen. ELISA: F Korkmaz, A Gumerova. qPCR: A Pallapati, G Burganova. Data analysis: F Korkmaz, F Sultana, V Laurencin, L Cullen, S Rojekar, D Lizneva, T Yuen. Animal maintenance: F Korkmaz, F Sen, U Cheliadinova, D Vasilyeva. Methodology: T Frolinger, T Yuen. Quality assurance: G Pevnev, A Macdonald, M Saxena, O Barak. Manuscript preparation: F Korkmaz, T Yuen, T Frolinger, M Zaidi. Funding acquisition: CJ Rosen, T Yuen, M Zaidi.
Corresponding authors
Ethics declarations
Competing interests
MZ is inventor on issued and pending patients on the use of FSH as a target for osteoporosis, obesity and Alzheimer’s disease. MZ, SR and TY are inventors on a pending patent on an FSH antibody that is formulated at ultrahigh concentration. The patents will be held by the Icahn School of Medicine at Mount Sinai, and MZ, SR and TY would be recipient of royalties, per institutional policy. The other authors declare no competing financial interests.
Ethics approval
All methods were performed in accordance with the relevant guidelines and regulations. Animal handling and use were compliant with the National Institutes of Health’s Guide for the Care and Use of Laboratory Animals, and approved by the Icahn School of Medicine at Mount Sinai Institutional Animal Care and Use Committee (IACUC Approval # 2018-0047).
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Korkmaz, F., Sims, S., Sen, F. et al. Gene–dose-dependent reduction of Fshr expression improves spatial memory deficits in Alzheimer’s mice. Mol Psychiatry 30, 2119–2126 (2025). https://doi.org/10.1038/s41380-024-02824-x
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/s41380-024-02824-x
This article is cited by
-
Targeting FSHR is a highly promising strategy for improving cognitive impairment in postmenopausal women
Molecular Psychiatry (2025)